{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(2)"],"submitter":["Timsit JF"],"funding":["Merck &amp; Co., Inc., Rahway, NJ, USA","MSD, France"],"pubmed_abstract":["<h4>Background</h4>This study describes the conditions of use of ceftolozane/tazobactam (C/T) and associated outcomes in French hospital settings.<h4>Methods</h4>This was a prospective, multicenter, French observational study. Patients who received at least 1 dose of C/T were included and followed up as per routine clinical practice, until stop of C/T.<h4>Results</h4>A total of 260 patients were enrolled between October 2018 and December 2019 in 30 centers across France. Of these, 177 (68.0%) received C/T as per indication of usage following the results of the antibiogram (documented cases). Among documented patients, the mean age was 61.8 years, 73.4% were males, and 93.8% presented with multidrug-resistant (MDR) bacteria at inclusion. C/T was most frequently prescribed for pneumonia (48.6%), bacteremia (14.7%), complicated intra-abdominal infections (13.0%), or complicated urinary tract infections (9.6%). <i>Pseudomonas aeruginosa</i> was the species most frequently isolated with 212 strains from 155 patients, and 96.2% of these strains were susceptible to C/T. The median duration of C/T treatment was 16.1 days (1-115, n = 176). Complete or partial cure was achieved in 71.7% of patients, C/T was discontinued upon adaptation to microbiology results in 11.3% of patients for the following reasons: treatment failure in 2.8%, death in 4.0%, adverse events in 1.7%, and other in 8.5%.<h4>Conclusions</h4>This is the first prospective observational study of C/T utilization in a health care setting enrolling many patients in France. C/T demonstrated a high rate of clinical effectiveness in MDR infections, confirming it as an effective treatment option for complicated infections in a high-risk population."],"journal":["Open forum infectious diseases"],"pagination":["ofae037"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10883286"],"repository":["biostudies-literature"],"pubmed_title":["Ceftolozane/Tazobactam for the Treatment of Complicated Infections in Hospital Settings-A French Real-world Study."],"pmcid":["PMC10883286"],"pubmed_authors":["Mootien J","Boutoille D","Tavares LM","Ruimy R","Ruiz F","Castan B","Timsit JF","Mackosso C","Brassac I","Akrich B","Bourge X"],"additional_accession":[]},"is_claimable":false,"name":"Ceftolozane/Tazobactam for the Treatment of Complicated Infections in Hospital Settings-A French Real-world Study.","description":"<h4>Background</h4>This study describes the conditions of use of ceftolozane/tazobactam (C/T) and associated outcomes in French hospital settings.<h4>Methods</h4>This was a prospective, multicenter, French observational study. Patients who received at least 1 dose of C/T were included and followed up as per routine clinical practice, until stop of C/T.<h4>Results</h4>A total of 260 patients were enrolled between October 2018 and December 2019 in 30 centers across France. Of these, 177 (68.0%) received C/T as per indication of usage following the results of the antibiogram (documented cases). Among documented patients, the mean age was 61.8 years, 73.4% were males, and 93.8% presented with multidrug-resistant (MDR) bacteria at inclusion. C/T was most frequently prescribed for pneumonia (48.6%), bacteremia (14.7%), complicated intra-abdominal infections (13.0%), or complicated urinary tract infections (9.6%). <i>Pseudomonas aeruginosa</i> was the species most frequently isolated with 212 strains from 155 patients, and 96.2% of these strains were susceptible to C/T. The median duration of C/T treatment was 16.1 days (1-115, n = 176). Complete or partial cure was achieved in 71.7% of patients, C/T was discontinued upon adaptation to microbiology results in 11.3% of patients for the following reasons: treatment failure in 2.8%, death in 4.0%, adverse events in 1.7%, and other in 8.5%.<h4>Conclusions</h4>This is the first prospective observational study of C/T utilization in a health care setting enrolling many patients in France. C/T demonstrated a high rate of clinical effectiveness in MDR infections, confirming it as an effective treatment option for complicated infections in a high-risk population.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Feb","modification":"2026-06-01T10:48:09.062Z","creation":"2025-02-19T03:51:21.26Z"},"accession":"S-EPMC10883286","cross_references":{"pubmed":["38390458"],"doi":["10.1093/ofid/ofae037"]}}